60th ERA congress, the Annual Nephrology Congress in Europe
15-18 June 2023
Milan, Italy
ENYO Pharma will attend and present at 60th ERA congress, the Annual Nephrology Congress in Europe
https://www.era-online.org/en/milan2023/
Multidisciplinary Day of Hepatology and Hepatic Transplantation
15 September, 2022
Lyon, France
ENYO Pharma sponsored and attent the Multidisciplinary Day of Hepatology and Hepatic Transplantation organized by Pr. Fabien Zoulim, Head of the Hepatology Department of the Hospices Civils de Lyon (HCL) the last September 15 at the Institute of Cognitive Sciences in Lyon, France. This annual seminar gathered around 150 professionals in hepatology.
HBV Forum 8 – Hepatitis B
21 June, 2022
London, UK
ENYO Pharma was attending HBV Forum 8 in London. The HBV Forum aims to advance the regulatory science for novel HBV therapeutic interventions and its associated morbidities in real time by providing an independent and neutral environment for ongoing multi-stakeholder dialogue.
AASLD-EASL HBV Endpoints 2022
3-4 June, 2022
Washington, US
ENYO Pharma was attending AASLD-EASL HBV Endpoints 2022 to share news on therapeutic endpoints, trial designs and safety concerns with regards to novel therapeutic approaches for treatment of chronic hepatitis B and D. It was a great opportunity to meet academic, regulatory, pharmaceutical communities and patients in liver disease area.
The Science of HBV Cure Meeting
30 May-2 June, 2022
Hybrid event-Singapour
ENYO Pharma and its collaborators were presenting the last results on Vonafexor’s effect in HBV at The Science of HBV Cure Meeting organized by Singapore Hepatology Conference.
“Antiviral effects of oral farnesoid X receptor agonist Vonafexor combined with pegylated interferon alpha2a in untreated patients with chronic hepatitis B”.
Latest Press Release 